Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
Date:3/25/2009

SHANGHAI, March 25 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for fourth-quarter and full-year 2008.

    (Logo:http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

    Highlights
    -- Total Company(1) Full-Year 2008 Net Revenues of $261.8 Million
       (Including $8.3 Million of Net Revenues from Discontinued Operations)
       and Adjusted EBITDA of $72.2 Million Achieve Company's Financial
       Guidance
    -- 74% Year-Over-Year Net Revenue Growth from Continuing Operations in
       Fourth Quarter of 2008, 33% Organic Net Revenue Growth for China-Based
       Businesses
    -- 87% Year-Over-Year Net Revenue Growth from Continuing Operations for
       Full-Year 2008, 45% Organic Net Revenue Growth for China-Based
       Businesses
    -- Fourth-Quarter and Full-Year 2008 Net Losses Reflect Non-Cash
       Impairment Charges Relating to Continuing and Discontinued AppTec
       Operations
    -- Construction Completed at Suzhou Toxicology Laboratory and Expanded
       Jinshan Manufacturing Plant
    -- Company Targets 2009 Net Revenues of $265-$275 Million, Including
       15-20% Net Revenue Growth in China-Based Laboratory Services
    -- Key 2009 Investments in Laboratory Services, Toxicology, and
       Manufacturing Services Expected to Drive Revenue Growth in 2010 and
       Beyond

Management Comment

"2008 was a year of extraordinary economic challenges, both in the worldwide economy and the healthcare industry," said Dr. Ge Li, Chairman and Chief Executive Of
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
2. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
3. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
4. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
5. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
6. Pharmatech 2.0: Introducing Pharmatech Oncology
7. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
8. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
9. WuXi PharmaTech Announces Third Quarter 2008 Results
10. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
11. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... WI (PRWEB) May 24, 2013 ... the discovery and development of calcium-binding proteins to ... of safety assessment study of apoaequorin ... international journal published for the British Industrial Biological ... study was to investigate potential adverse effects, if ...
(Date:5/23/2013)... May 23, 2013 Can economic incentives ... work motivate members of the public to increase their ... Johns Hopkins Carey Business School Assistant Professor ... Pointing to a large body of recent research that ... May 24, 2013, issue of Science that the World ...
(Date:5/23/2013)... The maker community is a contemporary ... They focus on learning practical skills while applying them ... bringing their ideas to life via crowdfunding. A subgroup ... making projects using biology. Glowing Plant has worked for ... them glow with bioluminescence genes, and has now pursued ...
(Date:5/23/2013)... May 23, 2013 BioTrends Research Group, ... firms for specialized biopharmaceutical issues, finds that, unaided, ... disease specialists reported that in the past six ... delaying treatment) in anticipation of the next generation ... ago, when only 6 percent reported that they ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... they,ve done it. What,s more, they did it with a ... Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley Lab) and the ... demonstration of GRIN for gradient index plasmonics, a ... of exotic optics, including superfast computers based on light rather ...
... and WOBURN, Mass., Jan. 24, 2011 Amgen (Nasdaq: ... that the companies have entered into a definitive acquisition ... Group, Inc., a privately held, venture-funded,  biotechnology company headquartered ... a novel oncolytic vaccine in Phase 3 clinical development, ...
... CEPH ) will hold a public memorial service to celebrate ... on February 1, 2011, at 6:00 p.m. at The Franklin Institute, ... Dr. Baldino founded Cephalon in 1987 and led the company from ... companies in the world. He was a recognized pioneer in the ...
Cached Biology Technology:GRIN plasmonics 2GRIN plasmonics 3GRIN plasmonics 4Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 2Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 3Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 4Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 5Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 6Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 7Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D. 2
(Date:5/23/2013)... undergo surgery or harsh treatments because science fails ... forms of the disease. Researchers at Case Western ... developing technology that allows patients to safely choose ... or take drastic measures. , The project is ... of biomedical engineering at Case Western Reserve and ...
(Date:5/23/2013)... largest and fastest growing open-access publishers, announces the ... Bioengineering and Biotechnology . , A broad ... Bioengineering and Biotechnology will provide a single ... biotechnology research to be disseminated and discussed. ... will provide an open-science and interactive web platform ...
(Date:5/22/2013)... Lung Screening Trial (NLST) investigators also conclude that ... with low-dose computed tomography (LDCT) versus chest X-ray ... paper is achievable at experienced screening centers in ... information to share with their patients about the ... following today,s publication in the New England ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Frontiers launches new open-access journal in Bioengineering and Biotechnology 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... alleviate food insecurity and food shortages around the ... to improve the nutritional content of food crops ... could lead to improved yields of food crops ... are also working on 'molecular farming' ?production of ...
... University have identified key compounds that stimulate stem cell ... to restored function for people affected by Parkinson's disease, ... disorders. These findings, which appear in the September 2006 ... to which compounds may be responsible for causing key ...
... Bioinformatics Institute and Duke University Medical Center have ... an important role in the development and virulence ... fungal pathogen that causes black spot disease on ... leaf loss in many economically important crops including ...
Cached Biology News:Are genomic technologies the answer to world hunger? 2Tearing down the fungal cell wall 2Tearing down the fungal cell wall 3
Rabbit polyclonal to hnRNP-U...
MAb to Mouse MHC Class I H-2Kd...
... GELase™ Agarose Gel-Digesting Preparation contains a ... for simple, quantitative recovery of intact DNA ... agarose gels following electrophoresis in TAE, TBE, ... be digested directly in the TAE, TBE, ...
... EKMax™ is a recombinant preparation of the ... Enterokinase is expressed and isolated from the ... purified enzyme preparation (2). It recognizes the ... after the lysine residue. The enzyme can ...
Biology Products: